A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- David P Rosenbaum, Ph.D.
Ardelyx, Inc.
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
111 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Ardelyx Investigative Site 114
Birmingham, Alabama, United States
- Ardelyx Investigative Site 149
Birmingham, Alabama, United States
- Ardelyx Investigative Site 100
Huntsville, Alabama, United States
- Ardelyx Investigative Site 103
Huntsville, Alabama, United States
- Ardelyx Investigative Site 145
Chandler, Arizona, United States
- Ardelyx Investigative Site 210
Phoenix, Arizona, United States
- Ardelyx Investigative Site 296
Phoenix, Arizona, United States
- Ardelyx Investigative Site 277
Tempe, Arizona, United States
- Ardelyx Investigative Site 187
Tucson, Arizona, United States
- Ardelyx Investigative Site 199
Tucson, Arizona, United States
- Ardelyx Investigative Site 269
Tucson, Arizona, United States
- Ardelyx Investigative Site 140
Harrisburg, Arkansas, United States
- Ardelyx Investigative Site 122
Little Rock, Arkansas, United States
- Ardelyx Investigative Site 161
Little Rock, Arkansas, United States
- Ardelyx Investigative Site 274
Little Rock, Arkansas, United States
- Ardelyx Investigative Site 129
North Little Rock, Arkansas, United States
- Ardelyx Investigative Site 105
Canoga Park, California, United States
- Ardelyx Investigative Site 143
Chula Vista, California, United States
- Ardelyx Investigative Site 146
Encino, California, United States
- Ardelyx Investigative Site 147
Encino, California, United States
- Ardelyx Investigative Site 107
Lomita, California, United States
- Ardelyx Investigative Site 112
North Hollywood, California, United States
- Ardelyx Investigative Site 110
Northridge, California, United States
- Ardelyx Investigative Site 294
San Diego, California, United States
- Ardelyx Investigative Site 108
Thousand Oaks, California, United States
- Ardelyx Investigative Site 178
Cutler Bay, Florida, United States
- Ardelyx Investigative Site 131
Fort Lauderdale, Florida, United States
- Ardelyx Investigative Site 130
Hialeah, Florida, United States
- Ardelyx Investigative Site 136
Hialeah, Florida, United States
- Ardelyx Investigative Site 287
Homestead, Florida, United States
- Ardelyx Investigative Site 106
Miami, Florida, United States
- Ardelyx Investigative Site 127
Miami Lakes, Florida, United States
- Ardelyx Investigative Site 123
Miami Springs, Florida, United States
- Ardelyx Investigative Site 126
Pompano Beach, Florida, United States
- Ardelyx Investigative Site 132
Port Orange, Florida, United States
- Ardelyx Investigative Site 150
St. Petersburg, Florida, United States
- Ardelyx Investigative Site 254
West Palm Beach, Florida, United States
- Ardelyx Investigative Site 234
Athens, Georgia, United States
- Ardelyx Investigative Site 138
Atlanta, Georgia, United States
- Ardelyx Investigative Site 148
Atlanta, Georgia, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Oct 2015
- Primary completion
- 31 Mar 2017
- Completion
- 30 Apr 2017
- Last update posted
- 21 Apr 2020
- Registered enrollment
- 606
- Registry id
- NCT02621892
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.